HC Wainwright Analysts Lower Earnings Estimates for Vericel

Vericel Co. (NASDAQ:VCEL - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2025 earnings estimates for Vericel in a report released on Wednesday, January 15th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.05 per share for the quarter, down from their prior estimate of $0.09. HC Wainwright has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Vericel's current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Vericel's Q4 2025 earnings at $0.26 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.86 EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $2.02 EPS.

VCEL has been the subject of several other reports. StockNews.com upgraded Vericel from a "sell" rating to a "hold" rating in a research report on Tuesday, December 24th. Truist Financial upped their target price on shares of Vericel from $61.00 to $67.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Canaccord Genuity Group reissued a "buy" rating and issued a $60.00 price target on shares of Vericel in a research note on Tuesday, November 19th. Stephens reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Vericel in a research note on Wednesday. Finally, BTIG Research upped their price target on Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $62.14.

Vericel Stock Up 4.8 %

Shares of Vericel stock traded up $2.72 during mid-day trading on Friday, reaching $59.07. 291,424 shares of the stock traded hands, compared to its average volume of 481,920. The stock has a market capitalization of $2.92 billion, a PE ratio of 984.66 and a beta of 1.72. The business has a 50-day moving average of $57.03 and a 200 day moving average of $50.03. Vericel has a fifty-two week low of $37.36 and a fifty-two week high of $61.49.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The firm had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million.

Hedge Funds Weigh In On Vericel

Several large investors have recently made changes to their positions in VCEL. International Assets Investment Management LLC increased its holdings in Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 619 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock worth $53,000 after buying an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock valued at $77,000 after buying an additional 322 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Vericel in the 3rd quarter valued at $92,000. Finally, Quantbot Technologies LP acquired a new position in Vericel during the 3rd quarter worth about $146,000.

Insiders Place Their Bets

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now owns 26,595 shares of the company's stock, valued at $1,595,700. This trade represents a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Paul K. Wotton sold 2,600 shares of Vericel stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $58.72, for a total transaction of $152,672.00. Following the sale, the director now owns 27,402 shares of the company's stock, valued at approximately $1,609,045.44. This represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,100 shares of company stock valued at $889,872 over the last quarter. 7.20% of the stock is owned by insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.